# Preoxygenation With Optiflow™ in Morbidly Obese Patients is Superior to Face Mask

> **NCT03009877** · NA · WITHDRAWN · sponsor: **Montefiore Medical Center**

## Conditions studied

- Obesity, Morbid

## Interventions

- **DEVICE:** Optiflow F&P 850™ System
- **DEVICE:** facemask
- **DRUG:** Rocuronium
- **DRUG:** Propofol
- **DRUG:** Fentanyl
- **DRUG:** Midazolam
- **DEVICE:** C-MAC Premium Video Intubation Platform-KARL STORZ

## Key facts

- **NCT ID:** NCT03009877
- **Lead sponsor:** Montefiore Medical Center
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2018-07
- **Primary completion:** 2019-05
- **Final completion:** 2019-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** withdrawn prior to IRB approval
- **Last updated:** 2018-03-27

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03009877

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03009877, "Preoxygenation With Optiflow™ in Morbidly Obese Patients is Superior to Face Mask". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03009877. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*